Kornimate/medical-research-clean huggingface dataset:
evaluation of retinal vascular density in high myopia without pathological myopic maculopathy using octa .

Conditions: High Myopia

Summary: study aiming to evaluate macular vascular density in high myopes without pathological myopic maculopathy in outpatient clinic in sohag teaching hospital using octa .

study design : this is a cross sectional observational study , of about 50 patients attending ophthalmology outpatient clinic at sohag teaching hospital . inclusion criteria : all myopic patients with axial high myopia (-6 spherical refractive error or more) attending the ophthalmology outpatient clinic . exclusion criteria : the exclusion criteria will include : * history of other any ocular diseases , systemic diseases that may affect the ocular circulation . * previous intraocular surgery or ocular injury . * any patient with pathological myopic maculopathy (epiretinal membrane, foveoschisis, macular holes, lamellar holes, lacquers cracks, choroidal neovascularization and retinal atrophy ) .

Eligibility criteria:
inclusion criteria wil include : * all myopic patients with axial high myopia (-6 spherical refractive error or more) of different age groups . exclusion criteria will include : * -history of other any ocular diseases , systemic diseases that may affect the ocular circulation . * previous intraocular surgery or ocular injury . * any patient with pathological myopic maculopathy as epiretinal membrane, foveoschisis, macular holes, lamellar holes, lacquers cracks, choroidal neovascularization and retinal atrophy .
intrauterine g-csf administration in rif

Conditions: Infertility

Summary: aim of this study is to investigate the effects of intrauterine g-csf on endometrial thickness, clinical pregnancy rate and live birth rate in a recurrent implantation failure (rif) group

this study was designed as a prospective randomized controlled trial with the involvement of 200 rif group patients.the procedure will perform by administering 30 miu of leucostim®(filgrastim \[g-csf\] 30miu/ml; dem medical, dong-a; south korea) through slow infusion into the endometrial cavity using a soft embryo transfer catheter. normal saline of 1 ml will be infused into the endometrial cavity in the same way in the control group. the standard icsi procedure will use for all patients, and fresh cycle embryos will be transferred on the third or fifth day.

Eligibility criteria:
inclusion criteria: * women under the age of 40 who met the rif definition * follicle-stimulating hormone (fsh) levels were \<15 iu/ml exclusion criteria: * patients with congenital uterine anomalies * patients with asherman's syndrome * patients with uterine cavity distorted by myoma or endometrial polyps * patients with confirmed endometriosis or endometrioma * patients for whom g-csf was contraindicated (active infections, kidney disease, sickle cell anemia, malignancies, chronic neutropenia)

Keywords: endometrium g-csf recurrent implantation failure
observational study of lumryz in narcolepsy

Conditions: Narcolepsy

Summary: this is an observational study of lumryz prescribed in clinical practice. patients are asked if they would be willing to complete questionnaires over a 4-month period after starting lumryz. the questionnaires ask about narcolepsy symptoms, experience with lumryz, and quality of life.


Eligibility criteria:
inclusion criteria: * adults with narcolepsy * oxybate naive or prior treatment with twice-nightly oxybate * access to smart phone, tablet or laptop with reliable internet connection * able to read/understand english * written informed consent and ability to comply with schedule exclusion criteria: * already using lumryz * clinical or mental health condition excluded by lumryz label * any other condition/situation that would adversely impact participation
double-blind, double dummy, randomized comparison study to evaluate the efficacy and safety of valdecoxib 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of osteoarthritis of the knee

Conditions: Osteoarthritis; Knee

Summary: this study was performed to demonstrate that treatment with valdecoxib 10 mg daily (qd) was at least as effective as with naproxen 500 mg twice daily (bid), a standard non-steroidal anti-inflammatory drug (nsaid), when taken for 6 weeks in korean subjects with symptomatic osteoarthritis (oa) of the knee. secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg qd taken for 6 weeks in korean subjects with symptomatic oa of the knee.


Eligibility criteria:
inclusion criteria: * korean outpatients with symptomatic radiologic evidence of oa of the knee (diagnosed according to the modified american college rheumatology criteria) * patient's assessment of arthritis pain measurement of at least 40 mm on vas * patients had not received any nsaids or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the baseline visit exclusion criteria: * diagnosis of inflammatory arthritis, gout, pseudogout, paget's disease, or any chronic pain syndrome that, in the investigator's opinion, would interfere with the assessment of the index knee * symptomatic anserine bursitis or acute joint trauma of the index knee * arthroscopy performed on the index knee within the past 12 months * complete loss of articular cartilage of the index knee * administration of oral, or intramuscular, intravenous, or soft tissue injections of corticosterosteroids within 4 weeks prior to screening visit * administration of intra-articular injection of corticosteroids or hyaluronic acid preparation in the index knee within 3 months or 6 months, respectively

Keywords: knee, oa patients
koppeling: help from your own circle

Conditions: Children of Parents With a Mental Illness (COPMI)

Summary: the goal of this randomized clinical trial is to test the effectiveness of the koppeling intervention that aims at unburdening copmi (children of parents with a mental illness). copmi are at risk of overtaking the tasks of their parents when their parents are unable to fulfil such due to their psychiatric condition. by overtaking tasks and the urge to always take care of their parents, copmi often do not participate in outdoor activities, which are necessary for their socio-emotional development. moreover, insufficient socio-emotional development and parentification are risk factors for the development of psychiatric conditions. koppeling is an intervention for copmi families that focuses on activating the social networks of the families. within koppeling, a strategic plan will be developed and carried out with the goal of receiving support from the social network that will overtake tasks of the family to unburden copmi. this study aims to answer the following questions: 1. to what extent does koppeling lead to an increase in quality of life (qol) among copmi? 2. to what extent does koppeling lead to an increase in mental health among copmi? 3. to what extent does koppeling lead to a reduction of parenting stress among copmi parents? 4. to what extent does koppeling lead to an increase in outdoor activities among copmi? 5. how does koppeling affect the feelings of guilt of copmi when engaging in outdoor activities? 6. what pre-conditions are needed to make koppeling widely applicable? 7. what are the long-term effects of koppeling on the qol and psychological problems among copmi and parental stress among copmi parents? participants will participate in the ten-to-twelve-week long koppeling intervention. researchers will compare the intervention group with a waiting list control group to test the effect of koppeling on the qol and mental health of copmi and parental stress of parents.


Eligibility criteria:
inclusion criteria: * the family has children aged 0-18 living at home * the parental disorder influences the parent's (or parents') ability to carry out several important parental tasks, placing their offspring at risk of taking over these tasks exclusion criteria: - the family has no existing social network

Keywords: copmi prevention social participation mental illness
measures of mitochondria dysfunction in pd

Conditions: Parkinson Disease, Mitochondrial

Summary: this study evaluates metabolic and functional parameters in the skeletal muscle of parkinson's disease patients for comparison to a set of healthy age-matched controls.

the goal of this study is to identify the unique signature of bioenergetic markers and mitochondrial (dys)function in muscle of individuals with pd, who are 65-85 of age, read and speak english, have a hoehn \& yahr score between 2 and 3 (bilateral disease, not severely disabled) and have a clinical diagnosis of pd. bioenergetic markers and muscle functional properties will be compared to a control dataset collected over the last few years from healthy elderly subjects in the same age range to provide a foundation for future intervention studies.

Eligibility criteria:
inclusion criteria: * age 65-85 years. * ability to attend a 3-hour study visit in seattle, wa. * ability to read and speak english. * hoehn \& yahr stage 2-3. (bilateral disease, not severely disabled.) exclusion criteria: * any contra-indication to magnetic resonance imaging * a history of epilepsy, stroke, brain surgery, or structural brain disease. * the presence of other serious illnesses * current or recent enrollment in a clinical trial involving an investigational product or device. * supplementation with nad, nicotinamide mononucleotide (nmn), nicotinamide riboside (nr), and other nutraceuticals designed to target nad for 30 days prior to baseline study visit. * current drug or alcohol use or dependence. * inability/unwillingness to provide informed consent. (e.g. diagnosis of dementia, confusion about study goals or participation.) * acute infection (e.g. upper respiratory, dermal) in the previous 30 days. * right limb tremor or dyskinesia that cannot be comfortably controlled for 90 minutes.

Keywords: parkinson disease mitochondria skeletal muscle bioenergetics
epidemiology of st131 in besançon university hospital

Conditions: Escherichia Coli Infections

Summary: the sequence type 131 (st131) is a predominant lineage among extraintestinal pathogenic escherichia coli. it plays a major role in the worldwide dissemination of e. coli that produce extended-spectrum beta-lactamase (esbl). the aim of this study was to describe the epidemiology of esbl producing st131clonal group in our university hospital. all patients with an infection due to esbl e. coli will be prospectively included for a 2-year period. st131 isolates will be identified and risk factors associated to st131 will be determined in comparison to non-st131 esbl e. coli.


Eligibility criteria:
inclusion criteria: * patients infected with esbl producing e. coli exclusion criteria: * patients known to be carrier or infected in the previous year, patients only colonised with esbl producing e. coli.

Keywords: e. coli extended-spectrum beta-lactamase molecular epidemiology risk factors
assessing induction of double strand breaks with androgen receptor partial agonist in patients on androgen suppression

Conditions: Prostate Cancer

Summary: this is a prospective, single-center, two-phase study to assess the efficacy of single pulsed-dose flutamide in creating double strand breaks (dsbs) in prostate cancer within patients receiving central androgen suppression and brachytherapy.

this is a prospective, single-center, two-phase study to assess the efficacy of single pulsed-dose flutamide in creating dsbs (double strand breaks) in prostate cancer within patients receiving central androgen suppression and brachytherapy. the initial phase is a 6-patient single-arm run-in phase to test feasibility and rule out futility of the intervention. all patients within the run-in phase will receive 50mg flutamide prior to brachytherapy and prostatic biopsy. if futility is ruled out (\>1 patients with dsbs on biopsy), then accrual will continue in the randomized, double-blind phase. subjects will be randomized in a 2:1 ratio (12:6 patients), for an all-trial total of 18 patients receiving flutamide vs 6 patients receiving placebo.

Eligibility criteria:
inclusion criteria: * histologically confirmed prostate cancer * at least one biopsy core with gleason 7 or higher disease * the patient has decided to undergo brachytherapy plus androgen suppression as treatment modality for his prostate cancer (with or without supplemental external beam radiation) * suitable volume of disease for biopsy: * clinically palpable disease corresponding to (ipsilateral to) any involved core on biopsy * signed study-specific consent form prior to registration exclusion criteria: * known hypersensitivity or allergic response to flutamide * severe hepatic impairment * major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up.
effect of oc000459 on moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine whether oc000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (ad).

the study will include patients with a th2 high eosinophilic phenotype who typically have more severe disease and are prone to flare.

Eligibility criteria:
inclusion criteria: 1. atopic dermatitis as defined by a score of at least 9 on the nottingham eczema severity score, stratified into moderate (score 9 to 11 inclusive) and severe (score 12 to 15 inclusive) disease. 2. fully documented history of the use of topical corticosteroids (tcs) and/or topical calcineurin inhibitors (tci). subjects without a fully documented history will be excluded from the study. 3. male and female subjects with moderate to severe atopic dermatitis treated with by tcs and/or tci (with or without emollients) at the time of screening and over the previous month. 4. subjects must have had at least 1 ad flare in the previous 6 months. exclusion criteria: 1. receipt of any forbidden medication including over the counter preparations and herbal medicines within 14 days of the first dosing day with the exception of paracetamol up to a maximum of 2g daily. 2. use of systemic steroids within 4 weeks of the screening visit, light therapy or immunosuppressants within 2 months of the screening visit. 3. use of nsaids. 4. subjects initially diagnosed with ad aged 2 years or over will be excluded unless they have either coexisting or a history of asthma and/or allergic rhinoconjunctivitis. 5. subjects with contact dermatitis will be excluded. 6. subjects with acute skin infection or acute disease flares. subjects with active flares during the screening to randomisation period (visits 1 to 2) may be managed according to normal clinical practice and be rescreened once their flares are no longer active. -
discovery and validate of multi-genetic biomarkers for capecitabine in chinese colorectal patients

Conditions: Colorectal Cancer; Capecitabine

Summary: at present, chemotherapy is widely used in the adjuvant treatment of colorectal cancer patients after surgery. capecitabine is one of the main chemotherapeutic drugs. but the effect is not good enough, the adverse reaction is serious, and the individual differences were significant. the present study shows that these problems are related to the differences in the exposure of capecitabine and its metabolites in different patients. the genetic biomarkers for capecitabine include drd, mthfr and tyms. mutations in these genes directly affect the expression of metabolic enzymes involved in capecitabine and control the concentration of capecitabine and its metabolites. however, these markers have been obtained through clinical trials in the united states, and their role in predicting the effectiveness or safety of capecitabine and its metabolites has not been validated in chinese cancer patients.the study was based on a case study of patients with colorectal cancer in china, and capecitabine as the primary postoperative chemotherapy regimen to verify whether the available biomarkers can be used to predict the effectiveness and safety of capecitabine. to clarify the effect of capecitabine on endogenous metabolites, and to study the mechanism of its effect, so as to discover new biomarkers.


Eligibility criteria:
inclusion criteria: 1. more than 18 years old; 2. patients with colon cancer diagnosed by biopsy (regardless of cancer stage); 3. received postoperative containing capecitabine chemotherapy; 4. volunteer to participate in the experiment exclusion criteria: 1. pregnant and lactating women; 2. patients with hypersensitivity to fluorouracil or severe metabolic failure; 3. patients with severe infection; 4. patients with other cancers other than colorectal cancer within the first five years of colorectal cancer surgery;

Keywords: biomarks colorectal cancer capecitabine gene polymorphism
evaluation of an oral microbiota-based therapeutic as a treatment option for psc

Conditions: Primary Sclerosing Cholangitis

Summary: this pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (mtt) inpatients with primary sclerosing cholangitis (psc). this trial will inform development of future trials in treatment of psc.


Eligibility criteria:
inclusion criteria: * ages 18-76 * serum total bilirubin at screening ≤ 2x the upper limit of normal * absence of biliary obstruction and malignancy by ultrasound or equivalent imaging within 6 months of study entry * anticipated maintenance of current medication regimen through the treatment period (udca, azathioprine, corticosteroid, methotrexate, 5-asa, biologic therapy and/or probiotic) * 3-month washout period of obeticholic acid or other experimental therapies for psc * stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and/or video visits or correspondence. * informed consent exclusion criteria: * antibiotic therapy (except vancomycin) within 3 months or anticipated antibiotic use in the course of the mtt treatment * presence of complications of advanced psc, such as hepatic encephalopathy, ascites, history of esophageal varices, portal hypertension, hepato-renal syndrome, portopulmonary syndrome, and hepato-pulmonary syndrome * evidence for viral hepatitis (history of hepatitis c is eligible with undetectable hcv rna); hiv/aids * metabolic or inherited liver disease (e.g., wilson's, hemochromatosis, alpha-1-antitrypsin deficiency) * another disease involving bile ducts (e.g., primary biliary cholangitis, igg4-related cholangitis, secondary sclerosing cholangitis) * evidence of cirrhosis on the last magnetic resonance cholangiopancreatography (within 6 months) * pregnancy or attempting to become pregnant or breastfeeding. * history of liver transplantation, anticipated need for liver transplantation within 12- months from randomization, or a model of end stage liver disease (meld) score of ≥15 * active malignancy * active alcohol overuse (\>4 drinks per day for men, and \>2 drinks per day for women) * moderate-to-severe renal impairment with a calculated creatinine clearance of \< 45 ml/min * neutropenia (an absolute neutrophil count \< 0.5 x 109 cells/l) * history of allergic reaction to vancomycin * history of allergic reaction to amoxicillin or other beta-lactam antibiotics * any other conditions or abnormalities that, in the opinion of the investigator, may compromise the safety of the subject or interfere with the subject participating in or completing the study * total colectomy
enhancing the effectiveness of prolonged exposure among suicidal individuals with ptsd

Conditions: PTSD; Suicidal Ideation; Suicide, Attempted; Trauma, Psychological

Summary: the long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (ptsd). prolonged exposure (pe) and crisis response plan (crp) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. however, no studies to date have assessed their effectiveness when used in combination. in light of this knowledge gap, the primary objective of this study will be to test the effectiveness of pe augmented with crp as compared to pe with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid ptsd.

posttraumatic stress disorder (ptsd) is associated with a host of functional problems and negative outcomes, including occupational and marital dissatisfaction, violence, alcohol and substance abuse, and suicide. cognitive behavioral treatments tend to be the most highly efficacious treatments for ptsd. prolonged exposure (pe) therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure, psychoeducation, and controlled breathing training. preliminary evidence suggests that pe is associated with significant suicidal ideation (si) reductions. enhancing pe with procedures that have been shown to significantly reduce suicidal thoughts and behaviors could serve to further reduce suicide risk during and after treatment completion. the long-term goal of this project is to prevent suicides among individuals diagnosed with ptsd by integrating trauma-focused therapies with suicide-focused interventions. the primary objective of this pilot project is to test the efficacy of pe when enhanced with a crisis response plan utilizing self-report, behavioral, and ecological assessment methods to compare treatment effects.

Eligibility criteria:
inclusion criteria: * current diagnosis of ptsd or subthreshold ptsd; ability to speak and understand the english language; and ability to complete the informed consent process. exclusion criteria: * substance use disorder requiring medical management; imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).
prospective evaluation of decision and compliance with antimalarials in patients with systemic lupus

Conditions: Systemic Lupus Erythematosus

Summary: this study is a biomedical, open label, therapeutic strategy, interventional, non-randomized, multicenter study to evaluate the non compliance to antimalarials in patients with systemic lupus in the nord pas-de-calais region (france). it is conducted in two visits. these visits consist in obtaining blood sample, performing a clinical examination and filling in a questionnaire (quality of life, coping...). the goal for the noncompliants patients is to guide them towards the therapeutic education with professionals (nurses and physicians).


Eligibility criteria:
inclusion criteria: * patients with a systemic lupus with acr criteria (at least 4 criterias) * patients with antimalarials for at least 3 months with a minimum dose of 200 mg/day. exclusion criteria: * patients who refuse to sign the informed consent * patients who are under guardianship

Keywords: systemic lupus erythematosus antimalarials therapeutic education coping questionnaire masri questionnaire morisky medication adherence scale lupus quality of life internal medicine